All In Biotech

Drug Trial Radar · NCT00200499

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients With Mild to Moderate Hypertension

Last checked: Nov 20, 2026Latest source record: Dec 16, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 845 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

845

Actual

Start

Mar 2002

Primary completion

Not stated

Study completion Sep 2003

Sponsor

Lead sponsor
Mylan Bertek PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive therapy.

Conditions

  • Hypertension

Interventions

  • NebivololDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in average sitting diastolic blood pressure measured at trough drug plasma level at the end of the extension phase compared to baseline of NEB 202, NEB 302 or NEB 305.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mylan Pharmaceuticals Inc.

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.